Roufas et al. quantified the transcript levels of GZMA and PRF1 and showed that these vary tremendously across the different types of cancer; for example, in acute myeloid leukemia, pleural mesothelioma, sarcoma, and stomach cancer have high CYT levels; while on the other hand, in ovarian, liver, thyroid, esophageal, prostate cancers, glioblastoma, glioma, adrenocortical carcinomas, and uveal melanomathese, were very low. This evidence concerns the gene PRF1 and prostate carcinoma.